|
US20030225254A1
(en)
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
|
JP3443119B2
(ja)
|
1989-08-07 |
2003-09-02 |
ペプテック リミテッド |
腫瘍壊死因子結合リガンド
|
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
AU764629B2
(en)
|
1998-01-22 |
2003-08-28 |
Btg International Limited |
Inhibition of cytokine production
|
|
WO2000051637A1
(en)
*
|
1999-03-02 |
2000-09-08 |
Centocor, Inc. |
ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA
|
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
|
US7056695B2
(en)
|
2000-03-02 |
2006-06-06 |
Xencor |
TNF-α variants
|
|
US7446174B2
(en)
|
2001-03-02 |
2008-11-04 |
Xencor, Inc. |
Protein based TNF-α variants for the treatment of TNF-α related disorders
|
|
US7101974B2
(en)
|
2000-03-02 |
2006-09-05 |
Xencor |
TNF-αvariants
|
|
AU4541101A
(en)
*
|
2000-03-02 |
2001-09-12 |
Xencor Inc |
Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
|
US7244823B2
(en)
|
2000-03-02 |
2007-07-17 |
Xencor |
TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
|
|
US7687461B2
(en)
|
2000-03-02 |
2010-03-30 |
Xencor, Inc. |
Treatment of TNF-α related disorders with TNF-α variant proteins
|
|
US7662367B2
(en)
|
2000-03-02 |
2010-02-16 |
Xencor, Inc. |
Pharmaceutical compositions for the treatment of TNF-α related disorders
|
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
|
PL218992B1
(pl)
*
|
2002-07-19 |
2015-02-27 |
Abbott Biotech Ltd |
Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
|
|
US7842691B2
(en)
|
2002-10-15 |
2010-11-30 |
Celgene Corporation |
Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
|
|
US7101978B2
(en)
|
2003-01-08 |
2006-09-05 |
Applied Molecular Evolution |
TNF-α binding molecules
|
|
CA2536321A1
(en)
|
2003-08-29 |
2005-03-10 |
Pfizer Inc. |
Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
|
|
WO2005041877A2
(en)
*
|
2003-10-29 |
2005-05-12 |
Children's Medical Center Corporation |
Method of inhibiting rejection following organ transplantation
|
|
JP4503022B2
(ja)
|
2003-12-23 |
2010-07-14 |
ファイザー・インク |
新規キノリン誘導体
|
|
US7435799B2
(en)
|
2004-01-08 |
2008-10-14 |
Applied Molecular Evolution |
TNF-α binding molecules
|
|
KR101465456B1
(ko)
|
2005-05-16 |
2014-11-27 |
애브비 바이오테크놀로지 리미티드 |
미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
|
|
JP2008120722A
(ja)
*
|
2006-11-10 |
2008-05-29 |
Benesis Corp |
生物由来製品の偽薬
|
|
AU2010226442A1
(en)
|
2009-03-20 |
2011-10-13 |
Antares Pharma, Inc. |
Hazardous agent injection system
|
|
US9149809B2
(en)
|
2011-05-06 |
2015-10-06 |
Bio-Rad Laboratories, Inc. |
Thermal cycler with vapor chamber for rapid temperature changes
|